Krystal Historical Income Statement

KRYS Stock

USD 190.40 8.11 4.45%

Historical analysis of Krystal Biotech income statement accounts such as Interest Expense of 0.0 can show how well Krystal Biotech performed in making a profits. Evaluating Krystal Biotech income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Krystal Biotech's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Krystal Biotech latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Krystal Biotech is a good buy for the upcoming year.

Net Income Gross Profit

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Krystal Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

For more information on how to buy Krystal Stock please use our How to Invest in Krystal Biotech guide.

About Krystal Income Statement Analysis

Krystal Biotech Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Krystal Biotech shareholders. The income statement also shows Krystal investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Krystal Biotech Income Statement Chart

At this time, Krystal Biotech's Research Development is comparatively stable compared to the past year. EBITDA is likely to gain to about 18.8 M in 2024, despite the fact that Operating Income is likely to grow to (104.2 M).

Depreciation And Amortization Selling General Administrative Other Operating Expenses Research Development Total Operating Expenses

Depreciation And Amortization

The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Krystal Biotech. It is also known as Krystal Biotech overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Krystal Biotech's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Krystal Biotech current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Krystal Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

For more information on how to buy Krystal Stock please use our How to Invest in Krystal Biotech guide.At this time, Krystal Biotech's Research Development is comparatively stable compared to the past year. EBITDA is likely to gain to about 18.8 M in 2024, despite the fact that Operating Income is likely to grow to (104.2 M).

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	2.8M	4.1M	5.0M	5.3M
Interest Income	197K	5.2M	22.6M	23.8M

Depreciation And Amortization Interest Income

Krystal Biotech income statement Correlations

	Net Interest Income	Interest Income	Depreciation And Amortization	Interest Expense	Selling General Administrative	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Reconciled Depreciation	Non Operating Income Net Other
Net Interest Income		0.98	0.84	-0.14	0.88	0.89	-0.71	0.16	0.16	0.81	0.2	0.89	0.18	0.98	0.16	0.84	0.92
Interest Income	0.98		0.84	-0.05	0.89	0.89	-0.71	0.16	0.17	0.82	0.21	0.89	0.18	0.98	0.16	0.84	0.93
Depreciation And Amortization	0.84	0.84		0.28	0.99	0.99	-0.95	-0.34	-0.33	0.99	-0.29	0.99	-0.32	0.8	-0.34	1.0	0.74
Interest Expense	-0.14	-0.05	0.28		0.27	0.25	-0.5	-0.83	-0.82	0.33	-0.82	0.25	-0.83	-0.2	-0.83	0.27	-0.2
Selling General Administrative	0.88	0.89	0.99	0.27		1.0	-0.95	-0.28	-0.28	0.97	-0.23	1.0	-0.27	0.84	-0.28	0.99	0.78
Other Operating Expenses	0.89	0.89	0.99	0.25	1.0		-0.94	-0.27	-0.26	0.98	-0.22	1.0	-0.25	0.85	-0.27	0.99	0.79
Operating Income	-0.71	-0.71	-0.95	-0.5	-0.95	-0.94		0.57	0.57	-0.97	0.53	-0.94	0.56	-0.63	0.57	-0.95	-0.59
Net Income From Continuing Ops	0.16	0.16	-0.34	-0.83	-0.28	-0.27	0.57		1.0	-0.4	1.0	-0.27	1.0	0.27	1.0	-0.34	0.28
Ebit	0.16	0.17	-0.33	-0.82	-0.28	-0.26	0.57	1.0		-0.39	1.0	-0.26	1.0	0.28	1.0	-0.33	0.29
Research Development	0.81	0.82	0.99	0.33	0.97	0.98	-0.97	-0.4	-0.39		-0.35	0.98	-0.38	0.76	-0.4	0.99	0.7
Ebitda	0.2	0.21	-0.29	-0.82	-0.23	-0.22	0.53	1.0	1.0	-0.35		-0.22	1.0	0.32	1.0	-0.29	0.33
Total Operating Expenses	0.89	0.89	0.99	0.25	1.0	1.0	-0.94	-0.27	-0.26	0.98	-0.22		-0.25	0.85	-0.27	0.99	0.79
Income Before Tax	0.18	0.18	-0.32	-0.83	-0.27	-0.25	0.56	1.0	1.0	-0.38	1.0	-0.25		0.29	1.0	-0.32	0.3
Total Other Income Expense Net	0.98	0.98	0.8	-0.2	0.84	0.85	-0.63	0.27	0.28	0.76	0.32	0.85	0.29		0.27	0.8	0.95
Net Income	0.16	0.16	-0.34	-0.83	-0.28	-0.27	0.57	1.0	1.0	-0.4	1.0	-0.27	1.0	0.27		-0.34	0.28
Reconciled Depreciation	0.84	0.84	1.0	0.27	0.99	0.99	-0.95	-0.34	-0.33	0.99	-0.29	0.99	-0.32	0.8	-0.34		0.74
Non Operating Income Net Other	0.92	0.93	0.74	-0.2	0.78	0.79	-0.59	0.28	0.29	0.7	0.33	0.79	0.3	0.95	0.28	0.74

Click cells to compare fundamentals

Krystal Biotech Account Relationship Matchups

Krystal Biotech income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Net Interest Income	3.0M	832K	(1.3M)	5.2M	22.6M	23.8M
Interest Income	3.0M	832K	197K	5.2M	22.6M	23.8M
Depreciation And Amortization	748K	1.9M	2.8M	4.1M	5.0M	5.3M
Interest Expense	3.1M	1.0M	0.0	832K	1.5M	5.2M
Selling General Administrative	6.5M	15.1M	40.4M	77.7M	98.4M	103.3M
Gross Profit	(974K)	(1.9M)	(2.8M)	(4.1M)	47.6M	50.0M
Other Operating Expenses	22.1M	33.0M	68.3M	120.2M	160.4M	168.4M
Operating Income	(22.1M)	(33.0M)	(68.3M)	(145.2M)	(109.7M)	(104.2M)
Net Income From Continuing Ops	(19.1M)	(33.0M)	(69.6M)	(140.0M)	10.9M	11.5M
Ebit	(22.1M)	(32.2M)	(68.1M)	(149.3M)	12.9M	13.5M
Research Development	15.6M	17.9M	27.9M	42.5M	46.4M	48.8M
Ebitda	(21.3M)	(30.3M)	(65.3M)	(145.2M)	17.9M	18.8M
Cost Of Revenue	974K	1.9M	2.8M	4.1M	3.1M	1.8M
Total Operating Expenses	22.1M	33.0M	68.3M	120.2M	160.4M	168.4M
Income Before Tax	(19.1M)	(32.2M)	(69.6M)	(140.0M)	12.9M	13.5M
Total Other Income Expense Net	3.0M	832K	(1.3M)	5.2M	122.6M	128.8M
Net Income Applicable To Common Shares	(19.1M)	(32.2M)	(69.6M)	(140.0M)	(126.0M)	(119.7M)
Net Income	(19.1M)	(32.2M)	(69.6M)	(140.0M)	10.9M	11.5M
Income Tax Expense	(3.0M)	1.6M	2.7M	34.0M	2.0M	1.9M
Reconciled Depreciation	748K	1.9M	2.8M	4.1M	5.0M	5.3M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Krystal Stock Analysis

When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Krystal Historical Income Statement

About Krystal Income Statement Analysis

Krystal Biotech Income Statement Chart

Depreciation And Amortization

Other Operating Expenses

Total Operating Expenses

Krystal Biotech income statement Correlations

Krystal Biotech Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Krystal Biotech income statement Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Krystal Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Reconciled Depreciation	+ 1.0	Depreciation And Amortization
Other Operating Expenses	+ 1.0	Selling General Administrative
Total Operating Expenses	+ 1.0	Selling General Administrative
Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebit	+ 1.0	Net Income From Continuing Ops
Ebitda	+ 1.0	Net Income From Continuing Ops

Research Development	- 0.97	Operating Income
Reconciled Depreciation	- 0.95	Operating Income
Operating Income	- 0.95	Selling General Administrative
Operating Income	- 0.95	Depreciation And Amortization
Total Operating Expenses	- 0.94	Operating Income
Operating Income	- 0.94	Other Operating Expenses